Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma-Reference-Cited by-同舟云学术

Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma

Published:2021-11-17 Issue: Volume: Page:
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Kim Bo Hyun¹,Yu Su Jong²,Kang Wonseok³,Cho Sung Bum⁴,Park Soo Young⁵,Kim Seung Up⁶⁷^ORCID,Kim Do Young⁶⁷^ORCID

Affiliation:

1. Center for Liver and Pancreatobiliary Cancer National Cancer Center Goyang Republic of Korea

2. Department of Internal Medicine and Liver Research Institute Seoul National University College of Medicine Seoul Republic of Korea

3. Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Republic of Korea

4. Department of Internal Medicine Chonnam National University Medical School Gwangju Republic of Korea

5. Department of Internal Medicine, School of Medicine, Kyungpook National University Kyungpook National University Hospital Daegu Republic of Korea

6. Department of Internal Medicine Yonsei University College of Medicine Seoul Republic of Korea

7. Yonsei Liver Center Severance Hospital Seoul Republic of Korea

Funder

Eisai Korea

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgh.15727

Reference57 articles.

1. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

2. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. NCCN(2020)NCCN clinical practice guidelines: hepatobiliary cancers(version 5.2020).https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf(Accessed 12 Jan 2021).

4. Lenvima USPrescribing information(2020). Available from:http://www.lenvima.com/pdfs/prescribing‐information.pdf(Accessed 5 March 2021).

5. European Medicines Agency(2020).LENVIMA (lenvatinib): summary of product characteristics.https://www.ema.europa.eu/en/documents/product‐information/lenvima‐epar‐product‐information_en.pdf. Accessed 2 March 2021.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma;Pakistan Journal of Medical Sciences;2023-09-11

2. Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical;Molecules;2023-06-09

3. L-carnitine prevents lenvatinib-induced muscle toxicity without impairment of the anti-angiogenic efficacy;Frontiers in Pharmacology;2023-04-06

4. Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study;Cancer Medicine;2023-02-15

5. Outcomes of the Sequential Treatment of Unresectable Hepatocellular Carcinoma Using Lenvatinib;Anticancer Research;2023-01-25